antibody-drug conjugate (ADC)
Showing 1 - 25 of >10,000
Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)
Withdrawn
- Relapsed Solid Neoplasm
- +2 more
- STI-3258
- (no location specified)
Jan 24, 2023
Light Chain (AL) Amyloidosis Trial (STI-6129)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
- (no location specified)
Jan 11, 2023
Light Chain (AL) Amyloidosis Trial in New York (STI-6129)
Recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
-
Duarte, California
- +3 more
Jan 12, 2023
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)
Not yet recruiting
- Breast Cancer
- +2 more
-
Concord, New South Wales, Australia
- +4 more
May 30, 2023
Solid Tumor Trial in United States (TR1801-ADC)
Active, not recruiting
- Unspecified Adult Solid Tumor, Protocol Specific
- TR1801-ADC
-
Los Angeles, California
- +4 more
Oct 30, 2022
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- FOR46
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 1, 2022
Solid Tumor Trial in United Kingdom, United States (Farletuzumab ecteribulin)
Recruiting
- Solid Tumor
- Farletuzumab ecteribulin
-
Tucson, Arizona
- +26 more
Jan 30, 2023
Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)
Not yet recruiting
- Advanced Solid Tumors
- LCB84
- Anti-PD-1 monoclonal antibody
-
Los Angeles, California
- +6 more
Jul 4, 2023
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,
Not yet recruiting
- Metastatic Penile Squamous Cell Carcinoma
- +3 more
- Enfortumab Vedotin
-
Phoenix, Arizona
- +2 more
Oct 23, 2023
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)
Not yet recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Biopsy
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023
HER2 Mutation-Related Tumors, HER2 Amplification Trial (ARX788)
Not yet recruiting
- HER2 Mutation-Related Tumors
- HER2 Amplification
- (no location specified)
Aug 23, 2021
Advanced/ Metastatic Solid Tumors Trial in Shanghai (FDA018-ADC)
Recruiting
- Advanced/ Metastatic Solid Tumors
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Dec 14, 2021
HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,
Active, not recruiting
- HIV Infection
- +3 more
- brentuximab vedotin
- +3 more
-
Clamart, France
- +5 more
Aug 11, 2022
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Relapsed/Refractory Multiple Myeloma Trial in Worldwide (Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose
Completed
- Relapsed/Refractory Multiple Myeloma
- Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
- Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
-
Phoenix, Arizona
- +10 more
Mar 25, 2022
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)
Not yet recruiting
- Acute Myeloid Leukemia
- Myeloid Neoplasm
- Biospecimen Collection
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 5, 2023
DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial
Not yet recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 5, 2023